CITIUS PHARMACEUTICALS 1 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSun, 03 May 2026 03:25:55 +0200https://images.finanzen.net/images/finanzen_net_neu.gifCITIUS PHARMACEUTICALS 1 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateTue, 23 Dec 2025 22:30:00 +0100https://www.finanzen.net/nachricht/aktien/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377928

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025

]]>https://www.finanzen.net/nachricht/aktien/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377928Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateTue, 23 Dec 2025 22:30:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377929

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

Completed $36 million ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377929Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimThu, 04 Dec 2025 14:37:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim-15335398

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, ]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim-15335398Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)Mon, 01 Dec 2025 18:00:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-announces-u-s-commercial-launch-of-lymphir-a-novel-cancer-immunotherapy-for-cutaneous-t-cell-lymphoma-ctcl-15325971

LYMPHIR now available nationwide

CRANFORD, N.J., Dec. ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-announces-u-s-commercial-launch-of-lymphir-a-novel-cancer-immunotherapy-for-cutaneous-t-cell-lymphoma-ctcl-15325971Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationFri, 21 Nov 2025 14:37:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-to-advance-commercial-launch-of-lymphir-with-verix-ai-integration-15304380

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-to-advance-commercial-launch-of-lymphir-with-verix-ai-integration-15304380